非小细胞肺癌寡转移的处理.pdfVIP

SPECIALSERIES:THORACICONCOLOGY:CURRENTANDFUTURETHERAPY

r

e

vPracticalManagementofOligometastatic

i

e

wNon–Small-CellLungCancer

a1,2341

KatieJasper,MD;BrendonStiles,MD;FionaMcDonald,MCRP,MD(Res);andDavidA.Palma,MD,PhD

r

t

i

c

l

e

s

aLocalablativetherapies,includingsurgeryorstereotacticradiotherapy(SABR),arebecominganintegral

b

scomponentinthetreatmentofoligometastaticdiseaseinnon–small-celllungcancer.Inthisreview,we

t

rsummarizerecentrandomizedevidencesupportingprogression-freesurvivalandoverallsurvivalbenefitsof

a

c

localablationinthesepatients,aswellasupcomingphaseIIIdatawhichshouldhelpusbetterunderstandthe

tidealtreatmentconditionsandprovidemoreinsightintotheoligometastaticstate.Sincepracticalmanagement

ofoligometastaticdiseaseinnon–small-celllungcancercanbechallenging,wediscussamodernframeworkto

identifypatient,tumor,andtreatmentcharacteristicsthatcanbestguidemanagement.

JClinOncol40:635-641.©2022byAmericanSocietyofClinicalOncology

INTRODUCTIONonetofivemetastaticlesions,butasperthe2020

Theemergenceofhighlyeffectivesystemictherapies,ESTRO-ASTRO